REACT Long COVID (REACT-LC)

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:9 publications

Grant number: MC_PC_20049

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2024
  • Known Financial Commitments (USD)

    $3,660,056.3
  • Funder

    UK Research and Innovation (UKRI)
  • Principal Investigator

    Professor Paul Elliott
  • Research Location

    United Kingdom
  • Lead Research Institution

    Imperial College London
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The REACT-Long COVID (REACT-LC) programme aims to characterise the genetic, biological, social and environmental signatures and pathways, and their inter-relationships, that underpin progression to Long COVID, and to understand the natura lhistory and long-term sequelae post-SARS-CoV-2 infection. To identify people with persistent symptoms who have not been hospitalised, we will use a sampling frame generated through repeated random population surveys of SARS-CoV-2 prevalence in the community, the REACT programme, which includes >1.5 million individuals with documented SARS-CoV-2 status (RTPCRor lateral flow test), including >30,000 with positive tests, 90% of whom have consented to be re-contacted and 85% to data linkage.The research is to be delivered through five integrated work packages (WPs). WP1 will describe variations in experience of Long COVID and develop patient reported outcomes (PROMS) in consultation with expert collaborators and through our patientand public partners. We will use online focus groups, discussion forums, individual interviews, and surveys on the VOICEGlobal platform, and recruit a panel of people with Long COVID to provide input on their symptoms and experience. In WP2 we will carry out detailed clinical phenotyping on 8,000 people (4,000 with Long COVID); 2,000 will have repeat measures at 4-6 months including 400 for T-cell function. The WP2 samples will be used in WP3 which includes multi-omic analysis, brain and inflammatory biomarkers. WP4 will use data from surveys sent to 30,000 test-positive and 90,000 test-negative on RTPCR/lateral flow in REACT, plus linked health data, to explore the social and environmental determinants of Long COVID and its long-term sequelae. WP5 is the data analysis and integration to identify genetic, biological, social and environmental determinants of Long COVID. We aim to identify key biomarkers and biological pathways underlying Long COVID and possible drug targets, as well as inequalities and social determinants of variations in outcome.

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

Long-term health impacts of COVID-19 among 242,712 adults in England.

SARS-CoV-2 rapid antibody test results and subsequent risk of hospitalisation and death in 361,801 people.

Patient and public involvement within epidemiological studies of long COVID in the UK.

Awareness and perceptions of Long COVID among people in the REACT programme: Early insights from a pilot interview study.

Characteristics and predictors of persistent symptoms post-COVID-19 in children and young people: a large community cross-sectional study in England.

The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis.

Predictive symptoms for COVID-19 in the community: REACT-1 study of over 1 million people.

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Understanding and tracking the impact of long COVID in the United Kingdom.